Analyst Price Targets — IMCR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 12:17 pm | — | Mizuho Securities | $38.00 | $32.51 | TheFly | Immunocore price target raised to $38 from $37 at Mizuho |
| January 7, 2026 5:43 am | Michael Yee | UBS | $55.00 | $32.85 | StreetInsider | UBS Assumes Immunocore Holdings (IMCR) at Buy |
| November 10, 2025 5:15 pm | Sean Laaman | Morgan Stanley | $36.00 | $34.53 | TheFly | Immunocore price target raised to $36 from $34 at Morgan Stanley |
| October 31, 2025 10:16 am | Eva Fortea Verdejo | Wells Fargo | $60.00 | $32.19 | TheFly | Immunocore initiated with an Overweight at Wells Fargo |
| March 7, 2025 1:37 pm | — | Morgan Stanley | $35.00 | $29.80 | TheFly | Immunocore assumed with an Equal Weight at Morgan Stanley |
| October 24, 2024 3:51 am | David Dai | UBS | $24.00 | $32.02 | StreetInsider | UBS Starts Immunocore Holdings (IMCR) at Sell |
| September 16, 2024 10:00 am | Justin Kim | Oppenheimer | $89.00 | $33.05 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Immunocore Holdings (IMCR) |
| September 12, 2024 7:54 am | Graig Suvannavejh | Mizuho Securities | $72.00 | $33.44 | StreetInsider | Mizuho Reiterates Outperform Rating on Immunocore Holdings (IMCR) |
| August 28, 2024 6:41 am | Patrick Trucchio | H.C. Wainwright | $100.00 | $35.71 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Immunocore Holdings (IMCR) |
| August 9, 2024 5:23 am | Peter Lawson | Barclays | $66.00 | $37.92 | TheFly | Immunocore price target lowered to $66 from $92 at Barclays |
Latest News for IMCR
Immunocore has transitioned from a rare-disease oncology company to a self-funded platform company with a validated commercial engine. KIMMTRAK's strong global sales, five-year survival data, and operating leverage underpin IMCR's ability to fund a broad pipeline without dilutive equity. Upcoming catalysts include pivotal readouts for tebentafusp and brenetafusp in melanoma, PRAME franchise expansion, and initial…
IMCR is seeing strong Kimmtrak sales growth and pursuing label expansion studies that could broaden its reach across melanoma treatments.
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position LQDA, IMNM, STOK and IMCR well in this volatile sector.
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Clinical benefit was…
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Clinical benefit was…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMCR.
U.S. House Trading
No House trades found for IMCR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.